Immuneering (IMRX) Accounts Payables (2020 - 2024)
Historic Accounts Payables for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $1.9 million.
- Immuneering's Accounts Payables rose 8.67% to $1.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.9 million, marking a year-over-year increase of 8.67%. This contributed to the annual value of $2.1 million for FY2023, which is 3305.98% down from last year.
- Immuneering's Accounts Payables amounted to $1.9 million in Q3 2024, which was up 8.67% from $2.6 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Accounts Payables peaked at $3.2 million during Q4 2022, and registered a low of $1.2 million during Q2 2022.
- Moreover, its 5-year median value for Accounts Payables was $1.9 million (2024), whereas its average is $2.1 million.
- Per our database at Business Quant, Immuneering's Accounts Payables skyrocketed by 12624.02% in 2022 and then plummeted by 3305.98% in 2023.
- Quarter analysis of 5 years shows Immuneering's Accounts Payables stood at $1.5 million in 2020, then fell by 5.82% to $1.4 million in 2021, then surged by 126.24% to $3.2 million in 2022, then crashed by 33.06% to $2.1 million in 2023, then decreased by 8.0% to $1.9 million in 2024.
- Its Accounts Payables was $1.9 million in Q3 2024, compared to $2.6 million in Q2 2024 and $2.3 million in Q1 2024.